Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Shares Outstanding (Weighted Average): 2022-2025

Historic Shares Outstanding (Weighted Average) for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $1.2 million.

  • InMed Pharmaceuticals' Shares Outstanding (Weighted Average) rose 257.44% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 257.44%. This contributed to the annual value of $1.2 million for FY2025, which is 188.87% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $1.2 million for FY2025, which was up 188.87% from $417,898 recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $1.2 million for FY2025, and its period low was $29,283 during FY2022.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $417,898 (2024), whereas its average is $597,165.
  • Data for InMed Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY surged of 468.28% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows InMed Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $29,283 in 2022, then soared by 468.28% to $166,410 in 2023, then soared by 151.13% to $417,898 in 2024, then spiked by 188.87% to $1.2 million in 2025.